2017年Q4美国风险投资行业观察报告（英文版）

Venture Monitor Summary - 4Q 2017

Core Content

The 4Q 2017 Venture Monitor report provides an in-depth look at the state of venture capital (VC) investment in the United States, highlighting key trends, performance metrics, and the evolving landscape of the venture ecosystem.

Main Points

VC Investment Activity

• Total Investment: In 4Q 2017, over $84.2 billion was invested in US venture-backed companies, marking the highest level since the dot-com era.
• Annual Total: This brought the full-year 2017 investment to a record high, surpassing $80 billion for the first time since the dot-com era.
• Deal Count: The number of deals in 4Q 2017 was the lowest since 2012, with only 1,772 companies receiving funding.
• Deal Size: Despite fewer deals, the total deal value surged by 16% YoY, with median deal sizes increasing across all stages.
• Late-Stage Deals: Median late-stage deal valuations rose to $250 million, a 85% increase from 2016.

Investor Behavior

• Disciplined Approach: Investors are more selective, focusing on stronger KPIs, which has led to fewer deals but higher valuations.
• SoftBank's Influence: The Vision Fund, with $100 billion in capital, has become a major player, participating in high-profile deals like WeWork's $3 billion investment and Compass' $450 million rounds.
• IPO Activity: While 2017 saw an increase in venture-backed IPOs (from 41 in 2016 to 58), the anticipated resurgence did not fully materialize, with companies staying private longer and valuations peaking in private markets.

Sector Analysis

• Biotech: Investment in biotech reached a 10-year high of $17.6 billion, driven by a focus on AI, genomics, and healthcare innovations.
• Fintech: Fintech investment grew to a record $6.5 billion in 2017, with major focus areas including alternative lending, payments, and blockchain.
• Unicorns: Unicorns (companies valued over $1 billion) attracted $19.1 billion in 2017, representing 23% of total VC investment and nearly 50% of the value from deals over $50 million.
• Early-Stage Investments: Early-stage deals saw a significant increase in size, with median deal sizes reaching $1 million, up 100% from five years prior.
• Angel & Seed Activity: Although angel and seed deal counts declined, the median deal size increased, and the number of companies raising first-round funding leveled off.

Market Dynamics

• Dry Powder: The amount of available capital (dry powder) has been substantial, with investors increasingly using private capital for growth rather than IPOs or M&A.
• Liquidity Challenges: Secondary sales have become more common to address liquidity issues for private companies, though they are not a complete solution.
• Public Policy Impact: The appointment of Scott Gottlieb as FDA Commissioner and the tax reform plan have positively influenced the biotech and broader venture ecosystem.

Legal and Investment Trends

• Cryptocurrencies: The rise of ICOs and blockchain investments has led to increased legal complexity, prompting firms like Perkins Coie to adopt a structured, three-step evaluation framework.
• Special Purpose Vehicles (SPVs): GPs are increasingly using SPVs to structure one-time investment funds, allowing for better follow-on investment opportunities.
• Fund Formation: Smaller funds are forming with more institutional backing, and the structure of these funds is becoming more tailored and cost-effective.

Regional and Sector Activity

• Regional Activity: The West Coast saw a rebound in deal value, while the Mid-Atlantic region remained steady.
• Sector Trends: Traditional sector boundaries are blurring, with biotech and fintech leading the charge. Software investment has declined, and life sciences/healthcare have become a major focus.

Key Information

• Total VC Investment in 2017: Over $84.2 billion in 4Q, with the annual total reaching a record high.
• Unicorn Investments: $19.1 billion invested in unicorns, representing 23% of total VC investment.
• Biotech Investment: $17.6 billion in 4Q, with companies like Grail and Ginkgo Bioworks making headlines.
• Fintech Investment: $6.5 billion in 2017, with growing interest in blockchain, insurtech, and real estate tech.
• Deal Size Growth: Median early-stage deal size increased by 20%, and late-stage deals grew significantly, with $50M+ deals accounting for nearly 70% of late-stage capital.
• Public Policy Impact: New leadership at the FDA and tax reforms are influencing the venture ecosystem, especially in biotech and M&A.
• Secondary Sales: These have grown in popularity due to liquidity challenges, though they are not a perfect solution.

Conclusion

2017 was a pivotal year for the venture industry, marked by record investment levels, a shift in investor behavior, and the emergence of new trends in biotech and fintech. Despite challenges in liquidity and IPO activity, the ecosystem continues to evolve, with a focus on innovation, strong KPIs, and the increasing role of large institutional investors like SoftBank. The future of venture capital appears to be shaped by these dynamics, with a growing emphasis on structured investment approaches and the integration of technology into traditional sectors.